Business
Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook
Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates
Advertisement
Topic
Novo
Business
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
Business
Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits
Walmart will offer Novo's Ozempic and Lilly's Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.
Business
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Business
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
Business
Two Indian nationals charged with smuggling counterfeit Ozempic from China: DOJ
The criminal indictment in Florida comes as the use of GLP-1 drugs such as Novo's Ozempic for weight loss has hit new highs among U.S. adults.
Business
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Business
Novo's new strategy hinges on something it can't manufacture: investor trust
Novo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.
Advertisement
Business
Novo defends diversification push as CEO eyes deals beyond obesity
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Business
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Business
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.